The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Практическое руководство Европейской ассоциации сердечного ритма 2018 года по применению пероральных антикоагулянтов, не являющихся антагонистами витамина K, у пациентов с фибрилляцией предсердий
2018-03-01
SCID: 54.1/nx438amf
Discuss with AI
anticoagulant managementatrial fibrillationdrug-drug interactionsnon-vitamin K antagonist oral anticoagulantsstroke prevention
Figures from the paper
Abstract (AI)
The current manuscript is the second update of the original Practical Guide, published in 2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-651; Heidbuchel et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467-1507]. Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF) and have emerged as the preferred choice, particularly in patients newly started on anticoagulation. Both physicians and patients are becoming more accustomed to the use of these drugs in clinical practice. However, many unresolved questions on how to optimally use these agents in specific clinical situations remain. The European Heart Rhythm Association (EHRA) set out to coordinate a unified way of informing physicians on the use of the different NOACs. A writing group identified 20 topics of concrete clinical scenarios for which practical answers were formulated, based on available evidence. The 20 topics are as follows i.e., (1) Eligibility for NOACs; (2) Practical start-up and follow-up scheme for patients on NOACs; (3) Ensuring adherence to prescribed oral anticoagulant intake; (4) Switching between anticoagulant regimens; (5) Pharmacokinetics and drug-drug interactions of NOACs; (6) NOACs in patients with chronic kidney or advanced liver disease; (7) How to measure the anticoagulant effect of NOACs; (8) NOAC plasma level measurement: rare indications, precautions, and potential pitfalls; (9) How to deal with dosing errors; (10) What to do if there is a (suspected) overdose without bleeding, or a clotting test is indicating a potential risk of bleeding; (11) Management of bleeding under NOAC therapy; (12) Patients undergoing a planned invasive procedure, surgery or ablation; (13) Patients requiring an urgent surgical intervention; (14) Patients with AF and coronary artery disease; (15) Avoiding confusion with NOAC dosing across indications; (16) Cardioversion in a NOAC-treated patient; (17) AF patients presenting with acute stroke while on NOACs; (18) NOACs in special situations; (19) Anticoagulation in AF patients with a malignancy; and (20) Optimizing dose adjustments of VKA. Additional information and downloads of the text and anticoagulation cards in different languages can be found on an EHRA website (www.NOACforAF.eu).
Key Findings
1
Covered topics include treatment eligibility, initiation and follow-up, adherence, switching therapies, pharmacokinetics, drug interactions, organ disease, anticoagulant measurement, dosing errors, overdose, and bleeding management.
2
NOACs are presented as an alternative to vitamin K antagonists for stroke prevention and have become the preferred choice, especially when anticoagulation is newly initiated.
3
The 2018 document is the second update of EHRA’s Practical Guide for using non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
4
The guide addresses unresolved practical questions about NOAC use through evidence-based recommendations for 20 concrete clinical scenarios.
Research Object
Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation
Research Subject
Practical clinical use, including eligibility, dosing, monitoring, adherence, interactions, and management of complications
Publication Details
Publication Date
2018-03-01
Journal
Publisher
ISSN
Cited by
2123
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai7
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation2015
Guidelines for the Early Management of Patients With Acute Ischemic Stroke2013
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation2014
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS2016
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS2016
2017 ESC/EACTS Guidelines for the management of valvular heart disease2017
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism2012
Cited by8
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)2020
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation2020
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)2019
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)2024
2020 ESC Guidelines for the management of adult congenital heart disease2020
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease2020
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)2019
Periodontitis and cardiovascular diseases: Consensus report2020